アジスロマイシン二水和物市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、地域別、競合別、2020～2035年

アジスロマイシン二水和物の世界市場は、2024年には4,440トンと評価され、2035年には8,280トンに達すると予測され、予測期間中に5.89％の年間複合成長率（CAGR）で成長すると予測されています。

アジスロマイシンの誘導体であるアジスロマイシン二水和物は、その幅広い抗菌活性により、製薬業界で重要な役割を果たしています。呼吸器感染症、皮膚感染症、性感染症などの治療に広く使用されています。この市場の主な原動力は、世界のヘルスケア意識の高まり、細菌感染症の罹患率の上昇、特に新興経済圏における手頃な価格の治療オプションの必要性です。2022年EU産業研究開発投資スコアボードによると、医療産業は2021年に約2,353億ユーロを研究開発（R&D）に割り当て、これは世界の企業研究開発支出の21.5%に相当します。

地域的には、北米と欧州が高度なヘルスケアインフラと薬剤耐性感染症の蔓延により、アジスロマイシン二水和物の需要をリードしています。しかし、アジア太平洋地域は、ヘルスケアへのアクセスの改善、人口の増加、細菌感染率の増加により、最も速い成長が見込まれています。さらに、オンライン薬局やeコマースプラットフォームの拡大により、ヘルスケアインフラが限られている地域でのアジスロマイシン二水和物へのアクセスが改善されています。

市場はまた、アジスロマイシン二水和物の製剤化とデリバリーにおける技術革新を目の当たりにしており、その中には薬剤の有効性と患者のコンプライアンスを高める新しい剤形や併用療法の開発も含まれています。さらに、特許切れによるジェネリック医薬品の増加により、アジスロマイシン二水和物はより手頃な価格となり、より多くの患者が入手しやすくなっています。しかし、規制の複雑さ、抗菌薬耐性の出現、特定の地域におけるより良い代替品の必要性などの課題は、市場の成長を妨げる可能性があります。このような課題にもかかわらず、アジスロマイシン二水和物の世界市場は、継続的な医療需要と医薬品開発の進歩により、今後も拡大を続けると予想されます。

主な市場促進要因

細菌感染の増加

主な市場課題

規制上の障壁と市場アクセス

主要市場動向

オンライン薬局とeコマースプラットフォームの成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のアジスロマイシン二水和物市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（APIグレードのアジスロマイシン二水和物、医薬品グレードのアジスロマイシン二水和物、研究グレードのアジスロマイシン二水和物）
  • 用途別（抗生物質、呼吸器感染症、性感染症、皮膚感染症）
  • 企業別（2024年）
  • 地域別
• 市場マップ

第6章 北米のアジスロマイシン二水和物市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のアジスロマイシン二水和物市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のアジスロマイシン二水和物市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のアジスロマイシン二水和物市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのアジスロマイシン二水和物市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan N.V.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Azithromycin Dihydrate Market was valued at 4.44 thousand tonnes in 2024 and is projected to reach 8.28 thousand tonnes by 2035, growing at a compound annual growth rate (CAGR) of 5.89% during the forecast period.

Azithromycin dihydrate, a derivative of azithromycin, plays a critical role in the pharmaceutical industry due to its broad-spectrum antimicrobial activity. It is widely used in the treatment of respiratory, skin, and sexually transmitted infections, among others. This market is primarily driven by increasing global healthcare awareness, the rising incidence of bacterial infections, and the need for affordable treatment options, especially in emerging economies. According to the 2022 EU Industrial R&D Investment Scoreboard, the health industry allocated approximately €235.3 billion to research and development (R&D) in 2021, which represented 21.5% of global business R&D expenditure.

Geographically, North America and Europe are leading the demand for azithromycin dihydrate, owing to their advanced healthcare infrastructure and the growing prevalence of drug-resistant infections. However, the Asia-Pacific region is expected to experience the fastest growth, driven by improving healthcare access, a growing population, and increasing rates of bacterial infections. Moreover, the expansion of online pharmacies and e-commerce platforms has improved access to azithromycin dihydrate in regions with limited healthcare infrastructure.

The market is also witnessing innovations in the formulation and delivery of azithromycin dihydrate, including the development of new dosage forms and combination therapies that enhance the drug's efficacy and patient compliance. Additionally, the increasing availability of generics, due to patent expirations, is making azithromycin dihydrate more affordable and accessible to a wider patient population. However, challenges such as regulatory complexities, the emergence of antimicrobial resistance, and the need for better alternatives in certain regions may hinder market growth. Despite these challenges, the Global Azithromycin Dihydrate Market is expected to continue its expansion due to ongoing medical demand and advancements in drug development.

Key Market Drivers

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections is one of the major drivers of the Global Azithromycin Dihydrate Market. With global population growth and urbanization, the spread of infectious diseases is becoming more widespread. Respiratory infections, including pneumonia, bronchitis, and sinusitis, are common conditions treated with azithromycin, which is known for its broad-spectrum antibiotic properties. Azithromycin dihydrate's effectiveness against a wide range of bacterial pathogens makes it a critical treatment option. The growing number of bacterial infections, particularly in emerging economies with expanding healthcare systems, is increasing demand for antibiotics such as azithromycin dihydrate. Furthermore, environmental factors such as rising air pollution are contributing to higher rates of respiratory infections, further driving the market need for azithromycin. Antibiotic resistance remains a growing global concern, and azithromycin dihydrate's ability to treat multi-drug-resistant organisms reinforces its role in the global healthcare system. This rising burden of bacterial infections continues to support market growth.

Key Market Challenges

Regulatory Barriers and Market Access

A significant challenge facing the Global Azithromycin Dihydrate Market is the complex and varied regulatory requirements across different regions. Regulatory authorities such as the U.S. FDA, EMA, and other local agencies have stringent standards for approval, including Good Manufacturing Practices (GMP) compliance and safety guidelines. Prolonged approval timelines can delay market entry and slow the pace of innovation. Moreover, increasing regulatory focus on antibiotic resistance and usage has led to stricter guidelines for azithromycin dihydrate's application. For instance, the Central Drug Standard Control Organisation (CDSCO) in India has flagged several batches of azithromycin dihydrate for not meeting quality standards. These regulatory hurdles can impede market access, affecting both the speed of innovation and competition in the market.

Key Market Trends

Growth of Online Pharmacies and E-commerce Platforms

The rise of online pharmacies and e-commerce platforms has become a key driver of the Global Azithromycin Dihydrate Market. With the increasing popularity of digital health services, patients now have greater access to medications such as azithromycin dihydrate through online pharmacies. This has revolutionized the pharmaceutical sector, especially in regions where traditional pharmacies are scarce or hard to reach. The convenience of online shopping, alongside the ability to compare prices and read reviews, has made it easier for consumers to obtain azithromycin dihydrate from trusted online sources, expanding its reach. Additionally, e-commerce platforms offer home delivery services, a benefit especially appreciated during the COVID-19 pandemic when patients preferred to avoid in-person pharmacy visits. Online pharmacies also offer competitive pricing, which is particularly advantageous in developing regions where affordability is critical. The growth of telemedicine further contributes to this trend, as virtual consultations with healthcare providers often result in prescriptions for antibiotics like azithromycin dihydrate that patients can easily order online. As digital infrastructure improves, the accessibility of azithromycin dihydrate through online platforms will continue to increase, driving market growth.

Key Market Players

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arvindo Pharma Limited
• Mylan N.V.

Report Scope

In this report, the Global Azithromycin Dihydrate Market has been segmented as follows:

By Product:

• API Grade Azithromycin Dihydrate
• Pharmaceutical Grade Azithromycin Dihydrate
• Research Grade Azithromycin Dihydrate

By Application:

• Antibiotics
• Respiratory Infections
• Sexually Transmitted Diseases
• Skin Infections

By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: In-depth analysis of major players in the Global Azithromycin Dihydrate Market.

Available Customizations

TechSci Research offers customization options for the Global Azithromycin Dihydrate Market report based on specific company needs. Customization options include:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Azithromycin Dihydrate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (API Grade Azithromycin Dihydrate, Pharmaceutical Grade Azithromycin Dihydrate, Research Grade Azithromycin Dihydrate)
  • 5.2.2. By Application (Antibiotics, Respiratory Infections, Sexually Transmitted Diseases, Skin Infections)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Azithromycin Dihydrate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Azithromycin Dihydrate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Azithromycin Dihydrate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Azithromycin Dihydrate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Azithromycin Dihydrate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Azithromycin Dihydrate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Azithromycin Dihydrate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Azithromycin Dihydrate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Azithromycin Dihydrate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Azithromycin Dihydrate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Azithromycin Dihydrate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Azithromycin Dihydrate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Azithromycin Dihydrate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Azithromycin Dihydrate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Azithromycin Dihydrate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Azithromycin Dihydrate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Azithromycin Dihydrate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Azithromycin Dihydrate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Azithromycin Dihydrate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Azithromycin Dihydrate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Azithromycin Dihydrate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Azithromycin Dihydrate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Azithromycin Dihydrate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Azithromycin Dihydrate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Teva Pharmaceutical Industries Ltd.
• 14.3. Sandoz International GmbH
• 14.4. Arbindo Pharma Limited
• 14.5. Mylan N.V.

15. Strategic Recommendations

16. About Us & Disclaimer